In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine, prodrugs.

@article{Radi2007InVO,
  title={In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine, prodrugs.},
  author={Marco Radi and Auke D. Adema and Jonathan R Daft and Jong Hyun Cho and Eveline K Hoebe and Lou-Ella M M Alexander and Godefridus J. Peters and Chung K Chu},
  journal={Journal of medicinal chemistry},
  year={2007},
  volume={50 9},
  pages={2249-53}
}
l-1,3-Dioxolane-cytidine, a potent anticancer agent against leukemia, has limited efficacy against solid tumors, perhaps due to its hydrophilicity. Herein, a library of prodrugs were synthesized to optimize in vitro antitumor activity against non-small cell lung cancer. N4-Substituted fatty acid amide prodrugs of 10-16 carbon chain length demonstrated… CONTINUE READING